Persons with HIV who have entered care but have viral load > 1500 copies/mL may be the source of the majority of new HIV infections in the United States. We followed patients engaged in continuity care in the Johns Hopkins HIV Clinical Cohort between January 2010 and August 2015. We estimated person-time spent with viral load > 1500 copies/mL while in care after antiretroviral therapy (ART) initiation, while in care, and while alive. Person-time was classified according to the most recent viral load measurement. Of 11,283.1 person-years in care on after ART initiation, 11,954.7 person-years in care and 13,990.0 total person-years of follow-up spent alive, 12.5, 14.8%, and between 12.6 and 27.2%, respectively (depending on assumptions about the viral load of persons lost to clinic) were spent with viral load > 1500 copies/mL. Patients with lower baseline CD4 cell count, younger age, black race, history of injection drug use, or baseline hazardous alcohol use spent more time with viral load > 1500 copies/mL after ART initiation.
Introduction
A primary goal of HIV treatment is to ensure persons with HIV achieve and maintain viral load suppression. Persons who are virally suppressed have substantially lower morbidity and mortality [1] . Furthermore, when considering the HIV epidemic from a population perspective, persons who are virally suppressed are practically non-infectious to their sexual and drug-sharing partners [2] . A viral load below 1500 copies/mL has been identified as an important threshold for stopping onward transmission of the HIV virus [3] .
In previous years, it was estimated that 49% of new infections were acquired from persons living with HIV who were not aware of their HIV status [4] , more recently, persons who are aware of their infection but incompletely retained in care have been thought to be the source of the majority of new HIV infections (61%) [5] . Based on cross-sectional definitions of retention in HIV care, antiretroviral therapy (ART) use and viral suppression, prior research has identified black and Hispanic men, black women and persons with a history of injection drug use (IDU) as less likely to be retained in care, and while retained, less likely to be on ART and less likely to be virally suppressed [6] [7] [8] [9] [10] [11] [12] . Some disparities in retention and viral suppression associated with race, sex, and HIV acquisition risk factor may have diminished in recent years [13] [14] [15] . Nevertheless, these same groups at highest risk for poor retention and poor viral suppression based on cross-sectional analyses may also be at highest risk of transmitting HIV to others.
However, cross-sectional analyses have dichotomized persons' viral loads across an entire year and classified individuals as suppressed or not suppressed for that period, when in reality, viral load typically fluctuates more frequently [10, 16, 17] . A different picture of the transmission potential of certain groups may emerge if viral load is measured longitudinally. Indeed, in separate, prior analyses comparing progression through the HIV care continuum (retention, ART initiation and viral suppression) of persons who injected drugs with those who did not, longitudinal and cross-sectional analyses yielded slightly different conclusions regarding the propensity of persons who injected drugs to be virally suppressed [13, 17] . Herein, we describe the transmission potential of different groups, based on time spent with viral load > 1500 copies/mL, after engagement in continuity care in a large, urban HIV clinic.
Methods

Study Sample
The Johns Hopkins HIV Clinical Cohort includes all adults ≥ 18 years of age who have enrolled in continuity care in the Johns Hopkins HIV Clinic since 1989 and who have agreed to share their data (> 90% of patients). Patient demographics, most likely route of HIV acquisition, and medical history is obtained from the patient upon enrollment and recorded in the medical record. Trained medical record abstractors abstract this information, as well as antiretroviral prescription start and stop dates, clinical diagnoses, visit attendance, and any indications of substance use (alcohol, cocaine, and heroin) every 6 months. Laboratory data are available for any laboratory tests run by Johns Hopkins Medical system or at either of two large commercial laboratories operating in the Baltimore area. These three laboratories conduct the overwhelming majority of viral load measurements for cohort patients. Collection of data on this cohort and its analysis have been approved by the Johns Hopkins Hospital institutional review board. Additional information on this cohort is available elsewhere [18] .
ART treatment guidelines were expanded to 'treat when CD4 cell count ≤ 500 cells/μL' in 2010 [19] and 'treat regardless of CD4 cell count' in 2012 [20] . Thus, we restricted our analysis to persons engaged in care in the cohort (defined as newly enrolling or returning for a visit, CD4 cell count, or HIV viral load) any time from January 1, 2010 through August 31, 2015 in order to study a time period when nearly all patients enrolled in the cohort would meet criteria for ART initiation. Approximately 90% of individuals present to care with CD4 cell count < 500 cells/ µL; mean CD4 cell count at entry to care has not increased appreciably over the last two decades [21, 22] .
Of 3164 patients engaged in care in the cohort during the study period, we excluded 127 who did not have a baseline (measured within the window 1 year prior to 1 year after start of analytic follow-up) viral load measurement and 16 patients who were missing a baseline CD4 cell count. The final study sample included 3021 patients.
Covariates
Race was recorded in the medical record based on selfreport and classified as black, white, or other. Upon enrollment in care, patients' most likely route of HIV acquisition is recorded in the medical record based on conversations between the patient and his or her provider. For this analysis, we classified persons based on their reported routes of HIV acquisition as those who injected drugs (PWID) or not, men who had sex with men (MSM) or not, or those who reported heterosexual risk of HIV acquisition; persons were allowed to belong to more than one risk group. Prior ART exposure was defined as history of initiation of ≥ 3 antiretroviral medications on the same day. Prior AIDS diagnosis was based on clinical diagnoses while patients were in care in the Johns Hopkins HIV Clinic or on patient self-reported medical history at enrollment. Any evidence of recent (within the prior 6 months) cocaine, heroin, or hazardous alcohol use was abstracted from the medical record every 6 months. Evidence of recent substance use is typically based on provider notes or problem lists in the electronic medical record, but may also include diagnoses of substance abuse or substance use disorders, or laboratory results. Because abstraction relied primarily on provider notes, strict quantity/frequency definitions of hazardous alcohol use were not possible, however hazardous alcohol use was generally defined as any evidence of binge drinking (≥ 4 drinks/occasion) or daily consumption of > 1 drink [23] . Baseline substance use was defined as the abstracted values most proximal to the start of analytic follow-up during the study period.
Analysis
Patients enrolled in the cohort were followed from their first measured viral load after January 1, 2010 (for patients enrolled prior to 2010) or enrollment into the cohort (for new patients) until death or administrative censoring on 31 August 2015. For the purposes of this analysis, we were interested in time spent with HIV RNA ≤ 1500 copies/ mL, which coincides with the threshold for a significantly increased risk for heterosexual HIV transmission in East African transmission studies [3] . While the threshold for HIV transmission among injection drug users or men who have sex with men may be higher or lower, the majority of patients in our study sample reported the may have acquired (and therefore may transmit) their HIV infection through heterosexual sex, so we felt justified using 1500 copies/mL as the threshold for transmission in this analysis. We classified person-time as ≤ 1500 copies/mL or > 1500 copies/mL according to the value of the most recent viral load measurement, carrying measurements forward until the next viral load measurement or as long as the patient was still in care in the Johns Hopkins HIV clinic. Person-time was classified as lost-to-clinic following the 12-month anniversary of patients' most recent viral load measurement, CD4 cell count, or attended clinic visit. Because the viral load of patients considered lost-to-clinic was unknown, our primary analyses focuses on the percentage of time patients spent under observation with viral load > 1500 copies/mL, overall and after ART initiation. However, because loss to clinical care may represent a substantial proportion of the total time persons with diagnosed HIV infection spend with unsuppressed viral load, we also report total person-time that patients spent above the threshold for transmission assuming either: (1) that while patients were lost-to-clinic their viral load was > 1500 copies/mL; or (2) that patients who were lost-to-clinic entered HIV care elsewhere and had a well-controlled viral load. These two assumptions represent the bounds on total time with viral load > 1500 copies/mL. Because carrying the last viral load measurement forward may misclassify person-time, we also conducted sensitivity analyses using a different strategy for classifying person-time as ≤ 1500 or > 1500 copies/mL: we assumed that log 10 viral load increased or declined linearly between two time points at which it was measured, and we assigned a date at which viral load crossed the 1500 copies/mL threshold according to that assumption for intervals bounded by one viral load measurement ≤ 1500 copies/ mL and one viral load measurement > 1500 copies/mL. If viral load measurement on either end of an interval was missing (e.g., if an interval started with viral load ≤ 1500 copies/mL ended with loss-to-clinic, assumed > 1500 copies/mL but without a measurement), we assigned log 10 viral load to be the median of all measured log 10 viral loads above or below the 1500 copy/mL threshold (1.64 when viral load ≤ 1500 copies/mL and 4.42 when viral load > 1500 copies/mL). Person-time was also classified as on ART following ART initiation using an intentionto-treat principle.
We report proportion of person-time in care after ART initiation, person-time in care and bounds on total person-time after enrollment into the cohort spent with viral load > 1500 copies/mL. We stratify our results by key patient characteristics including baseline demographics and recent substance use. To evaluate the association between patient characteristics and person-time with a viral load > 1500 copies/mL, we fit negative binomial regression models (to account for violations of the assumption of a Poisson model that mean and variance are equal) where the outcome was days spent with a viral load > 1500 copies/mL with an offset of either person-time in care after ART initiation, persontime in care or total person-time; patient characteristics were included as independent variables. Because retention in clinic is a possible mediator of associations between baseline covariates and time spent with HIV RNA > 1500 copies/mL, we also fit negative binomial regression models for number of days spent lost-to-clinic as a rate of number of person-days under observation overall. We fit all models using generalized estimating equations [24] to account for correlated outcomes within individuals.
Results
The majority of the 3021 persons included in this analysis were male (65%) and black (75%). Median age at the start of follow-up was 48 years [interquartile range (IQR): 40, 53]. Most persons had already initiated ART (80%). Of persons newly enrolled in the cohort during follow-up, 53% were ART-experienced and 75% of ART-naïve patients had a CD4 cell count ≤ 500 cells/μL. Median baseline CD4 cell count was 430 cells/µL (IQR: 234, 630). Over two-thirds of persons (69%) started follow-up with a viral load ≤ 1500 copies/mL (Table 1) . Patients were followed for a median of 5.7 years (IQR: 3.9, 5.7). Patients had a median of 10 viral load measurements during follow-up (IQR: 5, 15) and measurements occurred a median of 3.5 months apart (IQR: 2.2, 5.3).
The cohort contributed 13,990.0 person-years of followup, 11,954.7 years of which (85.5%) was classified as in care in the Johns Hopkins HIV Clinic ( Table 2 ). The majority of in-care person-time contributed was after ART initiation (11,283.1 person-years; 94.4% of in-care person-time). Among person-years in care, 1766.4 (14.8%) were spent with HIV RNA > 1500 copies/mL, and of person-years in care after ART initiation, 1405.2 (12.5%) were spent above 1500 copies/mL. Between 12.6% and 27.2% of all personyears were spent with HIV RNA > 1500 copies/mL, based on the assumption that person-time spent lost to clinic was either all below or above the viral load threshold for transmission.
Subgroups with the highest proportion of in-care person-years after ART initiation with HIV RNA > 1500 copies/mL included: black, female PWID (18.7%); white, female PWID (15.9%); black, male PWID (14.3%); and black women who did not report injection drug use as an HIV acquisition risk factor (non-IDU) (13.9%). Under the assumption that time lost to clinic was spent with HIV RNA > 1500 copies/mL (worst case scenario), subgroups with the highest overall proportion of person-years spent above the threshold for transmission were similar: white, female PWID (38.6%); white, male PWID (32.0%); and black, female PWID (31.6%). White, male non-IDU had the lowest proportion of overall person-time spent observed with HIV RNA > 1500 copies/mL or lost to clinic 1 3 (22.7%) and the lowest proportion of in-care person-years in care after ART initiation with HIV RNA > 1500 copies/ mL (4.8%).
Among person-years spent in care after ART initiation, when viral load is most likely to be undetectable, the rate of person-years spent with viral load > 1500 HIV RNA copies/mL was higher among younger patients compared to older patients, black patients compared to patients of white or other race, PWID, patients without AIDS at baseline, patients with baseline hazardous alcohol use, and patients with lower baseline CD4 cell count. Baseline cocaine and heroin use and heterosexual risk of HIV acquisition were also associated with higher rates of having viral load above the threshold for transmission, although these associations were not statistically significant at the α = 0.05 threshold (Table 3) .
Associations between patient characteristics and days spent above the viral load threshold for transmission among person-years in care followed very similar patterns to those described above. Among all person-years, under the assumption that time spent lost to clinic was spent > 1500 HIV RNA copies/mL, associations were again similar with the exception that black patients spent a similar amount of time as patients of white or other race with HIV RNA > 1500 copies/mL. This is because white and other race were associated with higher rates of loss-to-clinic (adjusted rate ratio [aRR] = 1.43, 95% CI 1.24, 1.64 and aRR = 1.35, 95% CI 0.98, 1.87, respectively) than blacks. Likewise, baseline substance use was associated with lower rates of loss-toclinic and thus the association between substance use and HIV RNA > 1500 copies/mL was weaker when person-time lost to clinic was assumed to be spent with viral load > 1500 copies/mL (Table 3) .
Classifying person-time as ≤ 1500 or > 1500 copies/mL according to the alternate method (described above) led to very similar conclusions as the primary analysis. Under the alternate method of classifying person-time, the association between black race and viral load > 1500 copies/mL was substantially weakened (Supplemental Table 1 ).
Discussion
HIV RNA > 1500 copies/mL is an important indicator of a high risk for transmission of HIV infection. Internationally, the targets of the United Nations Programme on HIV/AIDS (UNAIDS) for the proportion of HIV-diagnosed persons who are receiving ART and for the proportion of persons receiving ART who are virally suppressed are 90% [25] . In this cohort of persons engaged in continuity HIV care, 94% of in-care person-time was contributed after ART initiation, exceeding the UNAIDS target. However, only 88% of person-time in care after ART initiation was spent with HIV RNA ≤ 1500 copies/mL (a less strict definition of viral suppression, based on risk of HIV transmission). If, while persons were not engaged in care in the Johns Hopkins HIV Clinic they were also not suppressed, the proportion of time spent capable of transmitting HIV infection would be higher (27%). If persons lost to clinic remained virally suppressed (possibly by receiving care elsewhere), then the proportion of all person-time in this cohort spent capable of transmitting HIV infection would only be 13%. The true proportion of time spent infectious is likely somewhere between these two extremes.
The proportion of person-time in care that was spent with HIV RNA > 1500 copies/mL (15%) in our study was less than that found in a prior study to which our cohort contributed data (23%) [26] and to a study in the HIV Outpatient Study (24%) [27] . This may be explained by differences in the study populations, but also by the fact that our sample was in care during a slightly more recent time period Indeed, the proportion of in-care person-time that patients spent with HIV RNA > 1500 copies/mL has decreased significantly over time, both overall and while on ART [27] . Although mathematical modeling studies have demonstrated that test and treat strategies could meaningfully reduce HIV transmission [28, 29] most have assumed levels of viral suppression among persons diagnosed with HIV that have not been realized [7, 30, 31] . Although we observed high rates of viral load ≤ 1500 copies/mL, our cohort is restricted to persons who have engaged in continuity care within the Johns Hopkins HIV Clinic. Patients not linked to continuity care or not retained after an initial visit are less likely to achieve and sustain viral load suppression [10, 32, 33] . Rates of transmissible viral load among persons living with HIV in the Clinic catchment area are likely higher.
There were disparities in the proportion of person-years spent with HIV RNA > 1500 copies/mL. History of IDU, recent drug and hazardous alcohol use, black race, and younger age were all associated with greater time spent capable of transmitting HIV infection. We found some indication that the disparities in time spent with HIV viral load > 1500 copies/mL associated with black race may be, at least in some part, driven by retention in care. Our findings are consistent with prior literature showing poor HIV-related outcomes for these groups [7, 13, 17, 34, 35] and with the prior studies that looked specifically at time spent capable of transmitting HIV infection [26, 27] . Although we did not directly measure socioeconomic status and position, all of the patient characteristics found associated with greater time spent infectious are correlated with social and economic vulnerability [36] . While overall in the United States, HIV incidence is estimated to be falling among all demographic groups, disparities in the absolute rate of HIV incidence persist with black persons representing a disproportionate infection burden [37] . Targeting adherence interventions towards patients with high rates of viral load above the threshold for transmission is an important strategy for reducing HIV incidence.
Older age and higher CD4 cell count at baseline were associated with lower rate of viral load > 1500 copies/mL; this is unsurprising as these covariates may be markers of longer history of being in HIV care and thus more stable retention. Furthermore, older patients are more likely to adhere to ART and to achieve viral suppression, regardless of retention, than are younger patients [38, 39] .
Illicit drug and hazardous alcohol use was also associated with higher rates of HIV RNA > 1500 copies/mL, but our results must be interpreted cautiously. Physicians may have under-ascertained recent substance use or preferentially identified only the heaviest users. If only the most severe or debilitating substance use is being ascertained, we may have over-estimated the association between recent substance use and transmission potential [40] . Notably, we found that history of IDU as an HIV acquisition risk factor was a stronger predictor of HIV RNA > 1500 copies/mL than was recent cocaine or heroin use. This may be due to under-ascertainment of recent cocaine or heroin use, or may reflect behaviors associated with IDU as an acquisition risk factor that have a stronger effect on maintaining viral suppression. The relative rate of HIV RNA > 1500 copies/mL was similar for patients with a history of IDU and for patients with baseline hazardous alcohol use. Hazardous alcohol use is a modifiable risk factor for non-adherence to HIV treatment [34, 41] and integrating interventions to reduce alcohol misuse into routine HIV care [42, 43] may have a positive impact on subsequent HIV transmission. While retention was not an explicit focus of this investigation, we did see that our assumptions about viral load value while patients were lost-to-clinic had important implications for our conclusions about the time spent with viral load > 1500 copies/mL. Furthermore, loss-toclinic seemed to drive some of the racial/ethnic disparities we observed in time spent with viral load > 1500 copies/ mL. Several initiatives have been undertaken in our clinic to maximize retention in care. Starting with their initial clinic appointment and continuing longitudinally, patients are engaged with social workers to assist in maintaining insurance coverage, to identify barriers to clinic attendance (transportation, substance use, housing, etc.) and to assist in finding ways to lower these barriers. Prior to each scheduled clinic visit, patients are contacted both by letter and by telephone call to confirm planned attendance or to reschedule appointments if needed. At each visit, patients are asked by the registration staff whether their contact information (address, phone, personal contacts) has changed and new information is recorded. When a patient misses a scheduled visit, attempts are made by a member of the Patient Advocate staff to determine his or her whereabouts. Maryland has recently implemented a state-wide system to track medical care across the region (the Chesapeake Regional Information System) that can be accessed by all clinic providers to be aware of care being Table 3 Adjusted rate ratios and 95% confidence interval for associations between patient characteristics and days spent with viral load > 1500 HIV RNA copies/mL provided outside of our facility and if a patient remains in care at another location if not retained in care in our clinic. Finally, retention has been a focus of both patient and provider educational interventions to emphasize the importance of retention as a critical part of the HIV care continuum.
Our work is not without limitations. We did not monitor HIV viral load continuously; to do so is not feasible. Therefore, we had to make assumptions about the viral load in the time between two measurements. Our primary analysis carried the most recent viral load measurement forward. Our sensitivity analysis apportioned time between two viral load measurements on either side of the 1500 copy/mL viral load threshold according to the magnitude of the measurements and the time between measurements. Neither analysis could account for periods when the viral load was > 1500 copies/mL (but unmeasured) between two viral loads both measured to be ≤ 1500 copies/mL. Likewise, neither analytic method could absolve us from making assumptions about the viral load value when persons in the cohort were lost from clinic. Pharmacy refill data may provide additional information to inform our assumptions about the value of viral load when it is not measured; however, this information was not routinely available for all patients in our cohort. Additionally, we did not distinguish between viral load values > 1500 copies/mL, although higher values are likely related to a higher force of transmission per possible transmission event. While estimating the force of transmission would be a worthy goal, it was not the goal of this analysis.
In contrast to the prior work looking at time spent > 1500 HIV RNA copies/mL [26, 27] , the present analysis explored the influence of time spent lost to clinic on time spent with viral load > 1500 HIV RNA copies/mL. Under the assumption that lost to clinic is synonymous with lost to care and loss of viral load control, both recent substance use and race may not be as strongly associated with HIV RNA > 1500 copies/mL as when the assumption is that patients lost to clinic remain in care. In an era of near-universal ART treatment, we observed high rates of viral load ≤ 1500 copies/mL. Yet over a quarter of all person-time was spent with a viral load that is associated with a high risk of transmitting HIV infection. Persons who reported IDU as an HIV acquisition risk factor, black patients, women, patients with lower CD4 cell count at baseline, younger patients, and patients with recent hazardous alcohol use had the highest rates of viral load > 1500 copies/mL while in care and after ART initiation and should be targeted for interventions that would increase adherence to ART.
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